New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease
Identifieur interne : 001B53 ( Main/Exploration ); précédent : 001B52; suivant : 001B54New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease
Auteurs : Christopher G. Goetz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Anxiety, Anxiety (diagnosis), Anxiety (etiology), Anxiety (therapy), Compulsive Behavior (diagnosis), Compulsive Behavior (etiology), Compulsive Behavior (therapy), Depression, Depression (diagnosis), Depression (etiology), Depression (therapy), Hallucination, Hallucinations (diagnosis), Hallucinations (etiology), Hallucinations (therapy), Humans, Nervous system diseases, Parkinson Disease (complications), Parkinson disease, Parkinson's disease, anxiety, compulsiveness, depression, hallucinations, psychiatric impairment.
- MESH :
- complications : Parkinson Disease.
- diagnosis : Anxiety, Compulsive Behavior, Depression, Hallucinations.
- etiology : Anxiety, Compulsive Behavior, Depression, Hallucinations.
- therapy : Anxiety, Compulsive Behavior, Depression, Hallucinations.
- Humans.
Abstract
Increasing research efforts are focused on nonmotor aspects of Parkinson's disease (PD). Depression, anxiety, compulsivity (dopamine dysregulation symptoms), and hallucinations/psychosis are among these disorders, and all complicate the management of PD with negative influences on quality of life. There is a strong overlap between depression and apathy and likewise, depression and anxiety can coexist and require careful pharmacologic management. Dopamine dysregulation syndrome is linked to medication use and most clearly associated with dopamine agonists. In contrast, although hallucinations and psychosis do not occur unless patients with PD are treated with dopaminergic drugs, medication doses do not directly relate to this problem. Functional neuroimaging provides an excellent resource for investigating these behaviors as well as their anatomical and neurochemical bases. New treatments are being developed, but there have been very few large‐scale randomized clinical trials to test the relative roles of new or available agents for abating these problematic behaviors. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22636
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001810
- to stream Istex, to step Curation: 001810
- to stream Istex, to step Checkpoint: 000832
- to stream PubMed, to step Corpus: 001933
- to stream PubMed, to step Curation: 001933
- to stream PubMed, to step Checkpoint: 001750
- to stream Ncbi, to step Merge: 002A69
- to stream Ncbi, to step Curation: 002A69
- to stream Ncbi, to step Checkpoint: 002A69
- to stream Main, to step Merge: 001F89
- to stream PascalFrancis, to step Corpus: 000B77
- to stream PascalFrancis, to step Curation: 002142
- to stream PascalFrancis, to step Checkpoint: 000943
- to stream Main, to step Merge: 002530
- to stream Main, to step Curation: 001B53
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CCAB8C41D6A72AB809F0B2B5C31C816D24E6287C</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22636</idno>
<idno type="url">https://api.istex.fr/document/CCAB8C41D6A72AB809F0B2B5C31C816D24E6287C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001810</idno>
<idno type="wicri:Area/Istex/Curation">001810</idno>
<idno type="wicri:Area/Istex/Checkpoint">000832</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Goetz C:new:developments:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20187250</idno>
<idno type="wicri:Area/PubMed/Corpus">001933</idno>
<idno type="wicri:Area/PubMed/Curation">001933</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001750</idno>
<idno type="wicri:Area/Ncbi/Merge">002A69</idno>
<idno type="wicri:Area/Ncbi/Curation">002A69</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002A69</idno>
<idno type="wicri:Area/Main/Merge">001F89</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0193489</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B77</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002142</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000943</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Goetz C:new:developments:in</idno>
<idno type="wicri:Area/Main/Merge">002530</idno>
<idno type="wicri:Area/Main/Curation">001B53</idno>
<idno type="wicri:Area/Main/Exploration">001B53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010">2010</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">S1</biblScope>
<biblScope unit="page" from="S104">S104</biblScope>
<biblScope unit="page" to="S109">S109</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CCAB8C41D6A72AB809F0B2B5C31C816D24E6287C</idno>
<idno type="DOI">10.1002/mds.22636</idno>
<idno type="ArticleID">MDS22636</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Anxiety (diagnosis)</term>
<term>Anxiety (etiology)</term>
<term>Anxiety (therapy)</term>
<term>Compulsive Behavior (diagnosis)</term>
<term>Compulsive Behavior (etiology)</term>
<term>Compulsive Behavior (therapy)</term>
<term>Depression</term>
<term>Depression (diagnosis)</term>
<term>Depression (etiology)</term>
<term>Depression (therapy)</term>
<term>Hallucination</term>
<term>Hallucinations (diagnosis)</term>
<term>Hallucinations (etiology)</term>
<term>Hallucinations (therapy)</term>
<term>Humans</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>anxiety</term>
<term>compulsiveness</term>
<term>depression</term>
<term>hallucinations</term>
<term>psychiatric impairment</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Anxiety</term>
<term>Compulsive Behavior</term>
<term>Depression</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anxiety</term>
<term>Compulsive Behavior</term>
<term>Depression</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Anxiety</term>
<term>Compulsive Behavior</term>
<term>Depression</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Angoisse anxiété</term>
<term>Etat dépressif</term>
<term>Hallucination</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Increasing research efforts are focused on nonmotor aspects of Parkinson's disease (PD). Depression, anxiety, compulsivity (dopamine dysregulation symptoms), and hallucinations/psychosis are among these disorders, and all complicate the management of PD with negative influences on quality of life. There is a strong overlap between depression and apathy and likewise, depression and anxiety can coexist and require careful pharmacologic management. Dopamine dysregulation syndrome is linked to medication use and most clearly associated with dopamine agonists. In contrast, although hallucinations and psychosis do not occur unless patients with PD are treated with dopaminergic drugs, medication doses do not directly relate to this problem. Functional neuroimaging provides an excellent resource for investigating these behaviors as well as their anatomical and neurochemical bases. New treatments are being developed, but there have been very few large‐scale randomized clinical trials to test the relative roles of new or available agents for abating these problematic behaviors. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Illinois</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Illinois"><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</region>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:CCAB8C41D6A72AB809F0B2B5C31C816D24E6287C |texte= New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |